JP2010525826A - 癌を治療するためのｍｉｒ３４治療剤を含む組成物 - Google Patents

癌を治療するためのｍｉｒ３４治療剤を含む組成物 Download PDF

Info

Publication number
JP2010525826A
JP2010525826A JP2010506716A JP2010506716A JP2010525826A JP 2010525826 A JP2010525826 A JP 2010525826A JP 2010506716 A JP2010506716 A JP 2010506716A JP 2010506716 A JP2010506716 A JP 2010506716A JP 2010525826 A JP2010525826 A JP 2010525826A
Authority
JP
Japan
Prior art keywords
seq
strand
nucleic acid
guide strand
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525826A5 (enExample
Inventor
クレアリー，ミツシエル・エイ
ジヤクソン，エイミー・エル
リンズレイ，ピーター・エス
バーチヤード，ジユルジヤ
リム，リー・ピー
マグナス，ジル・エフ
Original Assignee
ロゼッタ インファーマティックス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロゼッタ インファーマティックス エルエルシー filed Critical ロゼッタ インファーマティックス エルエルシー
Publication of JP2010525826A publication Critical patent/JP2010525826A/ja
Publication of JP2010525826A5 publication Critical patent/JP2010525826A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010506716A 2007-05-03 2008-05-05 癌を治療するためのｍｉｒ３４治療剤を含む組成物 Pending JP2010525826A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92762107P 2007-05-03 2007-05-03
PCT/US2008/062689 WO2008137867A2 (en) 2007-05-03 2008-05-05 Compositions comprising mir34 therapeutic agents for treating cancer

Publications (2)

Publication Number Publication Date
JP2010525826A true JP2010525826A (ja) 2010-07-29
JP2010525826A5 JP2010525826A5 (enExample) 2011-06-23

Family

ID=39944228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506716A Pending JP2010525826A (ja) 2007-05-03 2008-05-05 癌を治療するためのｍｉｒ３４治療剤を含む組成物

Country Status (6)

Country Link
US (2) US8399248B2 (enExample)
EP (1) EP2152722B1 (enExample)
JP (1) JP2010525826A (enExample)
AU (1) AU2008247427A1 (enExample)
CA (1) CA2686165A1 (enExample)
WO (2) WO2008137867A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506791A (ja) * 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−３４の合成模倣体
US9642872B2 (en) 2010-09-30 2017-05-09 University Of Zurich Treatment of B-cell lymphoma with microRNA
JP2019069971A (ja) * 2012-07-13 2019-05-09 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
CA2857878A1 (en) * 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP2152722B1 (en) 2007-05-03 2016-04-27 Merck Sharp & Dohme Corp. Compositions comprising mir34 therapeutic agents for treating cancer
CA2689974A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
JP5513375B2 (ja) * 2008-05-07 2014-06-04 北海道公立大学法人 札幌医科大学 癌の検出方法および検出用キット、ならびに癌治療剤
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
EP2191834A1 (en) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Compositions and methods for treating retrovirus infections
LU91545B1 (en) 2009-03-27 2010-09-28 Univ Luxembourg Mirna as a prognostic diagnostic biomarker and therapeutic agent for breast cancer and other human associated pathologies
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
FR2948687B1 (fr) * 2009-07-29 2015-09-04 Centre Nat Rech Scient Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
EP2476758A4 (en) * 2009-09-07 2013-04-03 Yoshiki Murakami METHOD FOR PREDICTING THE THERAPEUTIC EFFECT ON CHRONIC HEPATITIS C
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
US9272053B2 (en) 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
WO2011151321A1 (en) * 2010-05-31 2011-12-08 Institut Curie Asf1b as a prognosis marker and therapeutic target in human cancer
CN102031309A (zh) * 2010-11-30 2011-04-27 华东师范大学 miRNA-34c化合物作为脑胶质瘤标志物的应用
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US20130028956A1 (en) 2011-07-29 2013-01-31 Andre Fischer Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
AU2012346899A1 (en) * 2011-12-01 2014-06-19 Cincinnati Children's Hospital Medical Center Materials and methods related to NSAID chemoprevention in colorectal cancer
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
CN109810977A (zh) 2012-05-26 2019-05-28 株式会社博纳克 具有递送功能的基因表达调控用单链核酸分子
EP3010514B1 (en) * 2013-06-16 2021-01-20 National University Corporation Tokyo Medical and Dental University Double-stranded antisense nucleic acid with exon-skipping effect
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
WO2015099187A1 (ja) 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
RU2020140209A (ru) 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
US11027023B2 (en) 2014-12-27 2021-06-08 Bonac Corporation Natural type miRNA for controlling gene expression, and use of same
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
EP3364996B1 (en) 2015-10-22 2021-08-25 University of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
CA3016592A1 (en) 2016-03-04 2017-09-08 Rhode Island Hospital Targeting microrna for cancer treatment
EP3216869B1 (en) 2016-03-09 2019-09-18 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of leukemia
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
CA3040483A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP4265725A3 (en) 2017-11-09 2023-12-27 Purmx Therapeutics, Inc. Pharmaceutical composition comprising mirna-3140 for use in treating cancer
CN107699565B (zh) * 2017-11-24 2020-05-22 苏州大学 微小rna及其在制备抗肿瘤药物中的应用
CN110791566B (zh) * 2019-10-29 2023-06-27 徐州市中心医院 人shcbp1基因的用途及相关产品
CN111304327B (zh) * 2020-02-24 2024-04-19 宋程 人grpel2基因的用途及相关产品
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN114010523B (zh) * 2021-11-05 2024-04-12 天津穗纳生物医药科技有限公司 皮肤抗衰剂及其应用
WO2025184661A1 (en) * 2024-03-01 2025-09-04 Wave Life Sciences Ltd. Double stranded oligonucleotide compositions and methods relating thereto

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070050146A1 (en) * 2004-05-14 2007-03-01 Itzhak Bentwich Micrornas and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177568A1 (en) * 1992-12-07 2002-11-28 Stinchcomb Dan T. Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20070032441A1 (en) * 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1628993A4 (en) 2003-05-16 2010-04-07 Rosetta Inpharmatics Llc METHOD AND COMPOSITIONS FOR RNA INTERFERENCE
US6882555B2 (en) 2003-06-18 2005-04-19 Lattice Semiconductor Corporation Bi-directional buffering for memory data lines
WO2005031002A2 (en) 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
JP2007523649A (ja) 2004-02-10 2007-08-23 サーナ・セラピューティクス・インコーポレイテッド 多機能短鎖干渉核酸（多機能ｓｉＮＡ）を用い、ＲＮＡ干渉を介した遺伝子発現の阻害
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
EP2290073A3 (en) * 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
JP5078904B2 (ja) 2005-11-21 2012-11-21 ジヨンソン・アンド・ジヨンソン・リサーチ・ピーテイワイ・リミテツド 多標的干渉ｒｎａならびにそれらの使用および設計方法
US7893975B2 (en) * 2006-10-13 2011-02-22 Apple Inc. System and method for processing images using predetermined tone reproduction curves
EP2087301B1 (en) * 2006-11-07 2018-11-14 Tiax LLC dehumidification system and method for dehumidification
WO2008088858A2 (en) 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
ATE553196T1 (de) 2007-02-27 2012-04-15 Rosetta Genomics Ltd Zusammensetzung und verfahren zur modulation von zellproliferation und zelltod
EP2152722B1 (en) 2007-05-03 2016-04-27 Merck Sharp & Dohme Corp. Compositions comprising mir34 therapeutic agents for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070050146A1 (en) * 2004-05-14 2007-03-01 Itzhak Bentwich Micrornas and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5009002735; ＬＩＭ　Ｌ．Ｐ．: ＮＡＴＵＲＥ Ｖ４３３　Ｎ７０２７, 20050217, Ｐ７６９-７７３, ＮＡＴＵＲＥ　ＰＵＢＬＩＳＨＩＮＧ　ＧＲＯＵＰ *
JPN6013012167; Ｄｅｖ　Ｃｅｌｌ Ｖｏｌ．５, 2003, ｐ．３５１-３５８ *
JPN6013012169; Ｃｅｌｌ Ｖｏｌ．１１５, 2003, ｐ．２０９-２１６ *
JPN6013012171; Ｃｅｌｌ Ｖｏｌ．１１５, 2003, ｐ．１９９-２０８ *
JPN6013012174; ＲＮＡ Ｖｏｌ．９, 2003, ｐ．１０３４-１０４８ *
JPN6013012178; Ｇｅｎｅｓ　Ｄｅｖ Ｖｏｌ．２０, 2006, ｐ．１７３２-１７４３，　Ｓｕｐｐｌｅｍｅｎｔａｌ　Ｒｅｓｅａｒｃｈ　Ｄａｔａ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642872B2 (en) 2010-09-30 2017-05-09 University Of Zurich Treatment of B-cell lymphoma with microRNA
JP2014506791A (ja) * 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−３４の合成模倣体
US9371526B2 (en) 2011-02-03 2016-06-21 Mirna Therapeutics, Inc. Synthetic mimics of miR-34
JP2016152804A (ja) * 2011-02-03 2016-08-25 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−３４の合成模倣体
JP2019069971A (ja) * 2012-07-13 2019-05-09 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
JP7004637B2 (ja) 2012-07-13 2022-02-04 ウェイブ ライフ サイエンシズ リミテッド キラル制御
US11643657B2 (en) 2012-07-13 2023-05-09 Wave Life Sciences Ltd. Chiral control

Also Published As

Publication number Publication date
EP2152722A4 (en) 2011-12-28
WO2008137867A3 (en) 2009-04-16
US8399248B2 (en) 2013-03-19
EP2152722A2 (en) 2010-02-17
US8378088B2 (en) 2013-02-19
US20110105583A1 (en) 2011-05-05
WO2008137867A2 (en) 2008-11-13
WO2008137862A2 (en) 2008-11-13
US20100227909A1 (en) 2010-09-09
WO2008137862A3 (en) 2009-02-19
CA2686165A1 (en) 2008-11-13
EP2152722B1 (en) 2016-04-27
AU2008247427A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
EP2152722B1 (en) Compositions comprising mir34 therapeutic agents for treating cancer
WO2009131887A2 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
JP2022078069A (ja) 二本鎖ＲＮＡによるα－１アンチトリプシンの特異的阻害のための方法及び組成物
US20110118337A1 (en) Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
US20090136957A1 (en) Methods and compositions for regulating cell cycle progression via the miR-106B family
EP3666896A1 (en) Therapeutic inhibition of lactate dehydrogenase and agents therefor
US20180187193A1 (en) Microrna inhibition for the treatment of inflammation and myeloproliferative disorders
JP2010503420A (ja) 慢性リンパ球性白血病におけるｍｉＲ−２９およびｍｉＲ−１８１によって制御されるＴＣＬ１発現
WO2011022316A1 (en) Mirnas dysregulated in triple-negative breast cancer
US20160362688A1 (en) Compositions and methods of using microrna inhibitors
US20190276831A1 (en) Lung cancer diagnostics and therapeutics with mir-660
JP2017006137A (ja) 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法
EP3261718B1 (en) Methods of detecting, diagnosing, and treating atherosclerotic plaque rupture
EP4129338A1 (en) Prevention or treatment of aneurysms using mir-33b inhibitor
CN118291625A (zh) 口腔鳞癌相关生物标志物及诊断和治疗方法
CN113195740A (zh) 在脑内出血和蛛网膜下腔出血中的血浆和脑脊液miRNA生物标志物
WO2017207690A1 (en) Prognostic relevance of mir-422a in head and neck squamous cell carcinoma
WO2011017089A1 (en) Mirna inhibition of six1 expression
US20120108457A1 (en) Mir-211 expression and related pathways in human melanoma
CN105886653B (zh) 一种子宫内膜癌的分子标记物
CN113924127A (zh) 在患有自发性脑内出血的患者中作为癫痫发作的生物标志物的微rna调节网络

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130827